Ginsenoside Rk2, a dehydroprotopanaxadiol saponin, alleviates alcoholic liver disease via regulating NLRP3 and NLRP6 inflammasome signaling pathways in mice

Jian Zou; Rujie Yang; Ruibing Feng; Jiayue Liu; Jian-Bo Wan

doi:10.1016/j.jpha.2023.05.005

Volume 13 Issue 9

Sep. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Analysis > 2023 > 13(9): 999-1012

Jian Zou, Rujie Yang, Ruibing Feng, Jiayue Liu, Jian-Bo Wan. Ginsenoside Rk2, a dehydroprotopanaxadiol saponin, alleviates alcoholic liver disease via regulating NLRP3 and NLRP6 inflammasome signaling pathways in mice[J]. Journal of Pharmaceutical Analysis, 2023, 13(9): 999-1012. doi: 10.1016/j.jpha.2023.05.005

Citation:

Jian Zou, Rujie Yang, Ruibing Feng, Jiayue Liu, Jian-Bo Wan. Ginsenoside Rk2, a dehydroprotopanaxadiol saponin, alleviates alcoholic liver disease via regulating NLRP3 and NLRP6 inflammasome signaling pathways in mice[J]. Journal of Pharmaceutical Analysis, 2023, 13(9): 999-1012. doi: 10.1016/j.jpha.2023.05.005

Citation:

Jian Zou, Rujie Yang, Ruibing Feng, Jiayue Liu, Jian-Bo Wan. Ginsenoside Rk2, a dehydroprotopanaxadiol saponin, alleviates alcoholic liver disease via regulating NLRP3 and NLRP6 inflammasome signaling pathways in mice[J]. Journal of Pharmaceutical Analysis, 2023, 13(9): 999-1012. doi: 10.1016/j.jpha.2023.05.005

PDF( 6589 KB)

Ginsenoside Rk2, a dehydroprotopanaxadiol saponin, alleviates alcoholic liver disease via regulating NLRP3 and NLRP6 inflammasome signaling pathways in mice

doi: 10.1016/j.jpha.2023.05.005

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China

Funds:

The work was financially supported by grants from the Research Committee of the University of Macau (Grant No.: MYRG2022-00020-ICMS), and the Science and Technology Development Fund, Macao SAR, China (File No.: 0074/2021/AFJ and 0052/2022/A1).

Received Date: Mar. 03, 2023
Accepted Date: May 08, 2023
Rev Recd Date: Apr. 19, 2023
Publish Date: May 13, 2023

Abstract

Abstract

Heavy alcohol consumption results in alcoholic liver disease (ALD) with inadequate therapeutic options. Here, we first report the potential beneficial effects of ginsenoside Rk2 (Rk2), a rare dehydroprotopanaxadiol saponin isolated from streamed ginseng, against alcoholic liver injury in mice. Chronic-plus-single-binge ethanol feeding caused severe liver injury, as manifested by significantly elevated serum aminotransferase levels, hepatic histological changes, increased lipid accumulation, oxidative stress, and inflammation in the liver. These deleterious effects were alleviated by the treatment with Rk2 (5 and 30 mg/kg). Acting as an nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inhibitor, Rk2 ameliorates alcohol-induced liver inflammation by inhibiting NLRP3 inflammasome signaling in the liver. Meanwhile, the treatment with Rk2 alleviated the alcohol-induced intestinal barrier dysfunction via enhancing NLRP6 inflammasome in the intestine. Our findings indicate that Rk2 is a promising agent for the prevention and treatment of ALD and other NLPR3-driven diseases.
- Alcoholic liver disease,
- Ginsenoside Rk2,
- NLRP3 inflammasome,
- NLRP6 inflammasome,
- Intestinal barrier dysfunction

FullText(HTML)

References(60)

References

H.K. Seitz, R. Bataller, H. Cortez-Pinto, et al., Alcoholic liver disease, Nat. Rev. Dis. Primers 4 (2018), 16.

M. Wang, L. Ma, Y. Yang, et al., N-3 Polyunsaturated fatty acids for the management of alcoholic liver disease: A critical review, Crit. Rev. Food Sci. Nutr. 59 (2019) S116-S129.

World Health Organization, Global status report on alcohol and health 2018. https://www.who.int/substance_abuse/publications/global_alcohol_report/en/. (Accessed 31 July 2023).

T.H. Frazier, A.M. Stocker, N.A. Kershner, et al., Treatment of alcoholic liver disease, Therap. Adv. Gastroenterol. 4 (2011) 63-81.

R. Ding, K. Tian, L. Huang, et al., Herbal medicines for the prevention of alcoholic liver disease: A review, J. Ethnopharmacol. 144 (2012) 457-465.

M. de Carvalho Ribeiro, G. Szabo, Role of the inflammasome in liver disease, Annu. Rev. Pathol. Mech. Dis. 17 (2022) 345-365.

J. Zou, S. Wang, Y. Wang, et al., Regulation of the NLRP3 inflammasome with natural products against chemical-induced liver injury, Pharmacol. Res. 164 (2021), 105388.

G. Szabo, T. Csak, Inflammasomes in liver diseases, J. Hepatol. 57 (2012) 642-654.

D.A. DeSantis, C.W. Ko, Y. Liu, et al., Alcohol-induced liver injury is modulated by Nlrp3 and Nlrc4 inflammasomes in mice, Mediators Inflamm. 2013 (2013), 751374.

R. Feng, L. Ma, M. Wang, et al., Oxidation of fish oil exacerbates alcoholic liver disease by enhancing intestinal dysbiosis in mice, Commun. Biol. 3 (2020), 481.

R.E. Mainz, S. Albers, M. Haque, et al., NLRP6 inflammasome modulates disease progression in a chronic-plus-binge mouse model of alcoholic liver disease, Cells 11 (2022), 182.

B. Le Dare, P.J. Ferron, T. Gicquel, The purinergic P2X7 receptor-NLRP3 inflammasome pathway: A new target in alcoholic liver disease? Int. J. Mol. Sci. 22 (2021), 2139.

Y. He, S. Varadarajan, R. Munoz-Planillo, et al., 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome, J. Biol. Chem. 289 (2014) 1142-1150.

R.C. Coll, A.A.B. Robertson, J.J. Chae, et al., A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases, Nat. Med. 21 (2015) 248-255.

H. Jiang, H. He, Y. Chen, et al., Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders, J. Exp. Med. 214 (2017) 3219-3238.

M. Cocco, C. Pellegrini, H. Martinez-Banaclocha, et al., Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease, J. Med. Chem. 60 (2017) 3656-3671.

C. Marchetti, B. Swartzwelter, F. Gamboni, et al., OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation, Proc. Natl. Acad. Sci. U S A 115 (2018) E1530-E1539.

H. He, H. Jiang, Y. Chen, et al., Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity, Nat. Commun. 9 (2018), 2550.

G. Jin, J. Lu, H. Lan, et al., Protective effect of ginsenoside Rh2 against Toxoplasma gondii infection-induced neuronal injury through binding TgCDPK1 and NLRP3 to inhibit microglial NLRP3 inflammasome signaling pathway, Int. Immunopharmacol. 112 (2022), 109176.

S. Normand, A. Delanoye-Crespin, A. Bressenot, et al., Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury, Proc. Natl. Acad. Sci. U S A 108 (2011) 9601-9606.

M. Wlodarska, C.A. Thaiss, R. Nowarski, et al., NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion, Cell 156 (2014) 1045-1059.

G.M.H. Birchenough, E.E.L. Nystrom, M.E.V. Johansson, et al., A sentinel goblet cell guards the colonic crypt by triggering Nlrp6-dependent Muc2 secretion, Science 352 (2016) 1535-1542.

M. Levy, C.A. Thaiss, D. Zeevi, et al., Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling, Cell 163 (2015) 1428-1443.

X. Mao, X. Qiu, C. Jiao, et al., Candida albicans SC5314 inhibits NLRP3/NLRP6 inflammasome expression and dampens human intestinal barrier activity in Caco-2 cell monolayer model, Cytokine 126 (2020), 154882.

G.Y. Chen, T.S. Stappenbeck, Mucus, it is not just a static barrier, Sci. Signal. 7 (2014), pe11.

X. Ji, L. Li, P. Lu, et al., NLRP6 exerts a protective role via NF-kB with involvement of CCL20 in a mouse model of alcoholic hepatitis, Biochem. Biophys. Res. Commun. 528 (2020) 485-492.

L. Ma, N. Ma, J. Cao, et al., Characterizing the influence of different drying methods on chemical components of Panax notoginseng leaves by heart-cutting two-dimensional liquid chromatography coupled to orbitrap high-resolution mass spectrometry, Food Chem. 369 (2022), 130965.

R. Ding, K. Tian, Y. Cao, et al., Protective effect of Panax notoginseng saponins on acute ethanol-induced liver injury is associated with ameliorating hepatic lipid accumulation and reducing ethanol-mediated oxidative stress, J. Agric. Food Chem. 63 (2015) 2413-2422.

M. Wang, X.-J. Zhang, F. Liu, et al., Saponins isolated from the leaves of Panax notoginseng protect against alcoholic liver injury via inhibiting ethanol-induced oxidative stress and gut-derived endotoxin-mediated inflammation, J. Funct. Foods 19 (2015) 214-224.

J. Shao, X. Ma, L. Qu, et al., Ginsenoside Rh4 remodels the periphery microenvironment by targeting the brain-gut axis to alleviate depression-like behaviors, Food Chem. 404 (2023), 134639.

W. Song, B. Dai, Y. Dai, Influence of ginsenoside Rh2 on cardiomyocyte pyroptosis in rats with acute myocardial infarction, Evid. Based Complement. Alternat. Med. 2022 (2022), 5194523.

Y. Liu, N. Liu, Y. Liu, et al., Ginsenoside Rb1 reduces D-GalN/LPS-induced acute liver injury by regulating TLR4/NF-κB signaling and NLRP3 inflammasome, J. Clin. Transl. Hepatol. 10 (2022) 474-485.

N.H. Tung, T.H. Quang, J.H. Son, et al., Inhibitory effect of ginsenosides from steamed ginseng-leaves and flowers on the LPS-stimulated IL-12 production in bone marrow-derived dendritic cells, Arch. Pharmacal Res. 34 (2011) 681-685.

X. Huang, J. Xiao, M. Wen, et al., Ginsenoside Rk2 protects against ulcerative colitis via inactivating ERK/MEK pathway by SIRT1, J. Environ. Pathol. Toxicol. Oncol. 41 (2022) 89-98.

A. Bertola, S. Mathews, S.H. Ki, et al., Mouse model of chronic and binge ethanol feeding (the NIAAA model), Nat. Protoc. 8 (2013) 627-637.

M. Wang, X. Zhang, L. Ma, et al., Omega-3 polyunsaturated fatty acids ameliorate ethanol-induced adipose hyperlipolysis: A mechanism for hepatoprotective effect against alcoholic liver disease, Biochim. Biophys. Acta BBA Mol. Basis Dis. 1863 (2017) 3190-3201.

J. Zou, C. Yan, J. Wan, Red yeast rice ameliorates non-alcoholic fatty liver disease through inhibiting lipid synthesis and NF-κB/NLRP3 inflammasome-mediated hepatic inflammation in mice, Chin. Med. 17 (2022), 17.

R. Jafari, H. Almqvist, H. Axelsson, et al., The cellular thermal shift assay for evaluating drug target interactions in cells, Nat. Protoc. 9 (2014) 2100-2122.

R. Feng, Y. Wang, C. He, et al., Gallic acid, a natural polyphenol, protects against tert-butyl hydroperoxide- induced hepatotoxicity by activating ERK-Nrf2-Keap1-mediated antioxidative response, Food Chem. Toxicol. 119 (2018) 479-488.

T. Xuan, G. Gong, H. Du, et al., Protective effect of pteryxin on LPS-induced acute lung injury via modulating MAPK/NF-κB pathway and NLRP3 inflammasome activation, J. Ethnopharmacol. 286 (2022), 114924.

B. Gao, R. Bataller, Alcoholic liver disease: Pathogenesis and new therapeutic targets, Gastroenterology 141 (2011) 1572-1585.

Q. Xu, R. Zhang, Y. Mu, et al., Propionate ameliorates alcohol-induced liver injury in mice via the gut-liver axis: Focus on the improvement of intestinal permeability, J. Agric. Food Chem. 70 (2022) 6084-6096.

J. Sun, J. Fu, L. Li, et al., Nrf2 in alcoholic liver disease, Toxicol. Appl. Pharmacol. 357 (2018) 62-69.

Y. Liu, J. Zhou, Y. Luo, et al., Honokiol alleviates LPS-induced acute lung injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via Nrf2 activation in vitro and in vivo, Chin. Med. 16 (2021), 127.

X. Yang, M. Lu, L. You, et al., Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology, Chin. Med. 16 (2021), 62.

Y. Cao, Y. Jiang, D. Zhang, et al., Protective effects of Penthorum chinense Pursh against chronic ethanol-induced liver injury in mice, J. Ethnopharmacol. 161 (2015) 92-98.

Y. Peng, B.A. French, B. Tillman, et al., The inflammasome in alcoholic hepatitis: Its relationship with Mallory-Denk body formation, Exp. Mol. Pathol. 97 (2014) 305-313.

R. Feng, J. Chen, C. Liu, et al., A combination of Pueraria lobata and Silybum marianum protects against alcoholic liver disease in mice, Phytomedicine 58 (2019), 152824.

A. Bertola, O. Park, B. Gao, Chronic plus binge ethanol feeding synergistically induces neutrophil infiltration and liver injury in mice: A critical role for E-selectin, Hepatology 58 (2013) 1814-1823.

K. Cui, G. Yan, C. Xu, et al., Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice, J. Hepatol. 62 (2015) 1311-1318.

J. Petrasek, S. Bala, T. Csak, et al., IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice, J. Clin. Invest. 122 (2012) 3476-3489.

J. Petrasek, A. Iracheta-Vellve, B. Saha, et al., Metabolic danger signals, uric acid and ATP, mediate inflammatory cross-talk between hepatocytes and immune cells in alcoholic liver disease, J. Leukoc. Biol. 98 (2015) 249-256.

X. Li, Q. Jin, Y. Zhang, et al., Inhibition of P2X7R-NLRP3 inflammasome activation by Pleurotus citrinopileatus: A possible protective role in alcoholic hepatosteatosis, J. Agric. Food Chem. 66 (2018) 13183-13190.

C. Bode, V. Kugler, J.C. Bode, Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess, J. Hepatol. 4 (1987) 8-14.

R. Rao, Endotoxemia and gut barrier dysfunction in alcoholic liver disease, Hepatology 50 (2009) 638-644.

L. Antoni, S. Nuding, J. Wehkamp, et al., Intestinal barrier in inflammatory bowel disease, World J. Gastroenterol. 20 (2014) 1165-1179.

K. Venuprasad, A.L. Theiss, NLRP6 in host defense and intestinal inflammation, Cell Rep. 35 (2021), 109043.

B. Seo, K. Jeon, S. Moon, et al., Roseburia spp. abundance associates with alcohol consumption in humans and its administration ameliorates alcoholic fatty liver in mice, Cell Host Microbe 27 (2020) 25-40.e6.

L. Wang, D.E. Fouts, P. Starkel, et al., Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation, Cell Host Microbe 19 (2016) 227-239.

G. Wang, Q. Wang, J. Bai, et al., Upregulation of intestinal NLRP6 inflammasomes after roux-en-Y gastric bypass promotes gut immune homeostasis, Obes. Surg. 30 (2020) 327-335.

Relative Articles

Supplements(0)

Cited By

Proportional views